Matches in SemOpenAlex for { <https://semopenalex.org/work/W2746456353> ?p ?o ?g. }
- W2746456353 endingPage "e442" @default.
- W2746456353 startingPage "e431" @default.
- W2746456353 abstract "Background In the CALGB (Alliance) 100104 study, lenalidomide versus placebo after autologous stem-cell transplantation (ASCT) was investigated for patients with newly diagnosed myeloma. That study showed improved time to progression and overall survival and an increase in second primary malignancies for lenalidomide at a median follow-up of 34 months. Here we report an updated intention-to-treat analysis of CALGB (Alliance) 100104 at a median follow-up of 91 months. Methods Patients were eligible for this randomised, double-blind, placebo-controlled, phase 3 trial if they had symptomatic disease requiring treatment; had received, at most, two induction regimens; and had achieved stable disease or better in the first 100 days after ASCT. We randomly assigned patients to either lenalidomide or placebo groups using permuted block randomisation, with a fixed block size of six. Randomisation was stratified by three factors: normal or elevated β2 microglobulin concentration at registration (≤2·5 mg/L vs >2·5 mg/L), previous use or non-use of thalidomide during induction therapy, and previous use or non-use of lenalidomide during induction therapy. The starting dose was two capsules (10 mg) per day, escalated to three capsules (15 mg) per day after 3 months. The primary endpoint was time to progression (time of progressive disease or death from any cause), with intention-to-treat analysis. This study is registered with ClinicalTrials.gov, identifier NCT00114101. New patients are no longer being recruited, but some patients remain on treatment and in follow-up. Findings Between April 14, 2005, and July 2, 2009, 460 patients were randomly assigned to receive either lenalidomide (n=231) or placebo (n=229). After three interim analyses, the study was unblinded at a median follow-up of 18 months, at which point 86 (67%) of 128 patients without progressive disease in the placebo group chose to cross over to the lenalidomide group. The median follow-up for the updated survival analysis, as of Oct 19, 2016, was 91 months (IQR 83·6–103·1). The median time to progression was 57·3 months (95% CI 44·2–73·3) for the lenalidomide group and 28·9 months (23·0–36·3) for the placebo group (hazard ratio 0·57, 95% CI 0·46–0·71; p<0·0001). The most common grade 3–4 adverse events were neutropenia (116 [50%] patients in the lenalidomide group and 41 [18%] patients in the placebo group) and thrombocytopenia (34 [15%] patients in the lenalidomide group and 12 [5%] patients in the placebo group). 18 (8%) haematological and 14 (6%) solid tumour second primary malignancies were diagnosed after randomisation and before disease progression in the lenalidomide group, compared with three (1%) haematological and nine (4%) solid tumour second primary malignancies in the placebo group. Three haematological and five solid tumour second primary malignancies in the placebo group were in the crossover subgroup. Interpretation Despite an increase in haematological adverse events and second primary malignancies, lenalidomide maintenance therapy after ASCT significantly improved time to progression and could be considered a standard of care. Funding The National Cancer Institute." @default.
- W2746456353 created "2017-08-31" @default.
- W2746456353 creator A5003055083 @default.
- W2746456353 creator A5005645874 @default.
- W2746456353 creator A5005732386 @default.
- W2746456353 creator A5007847102 @default.
- W2746456353 creator A5011276712 @default.
- W2746456353 creator A5012400900 @default.
- W2746456353 creator A5015342719 @default.
- W2746456353 creator A5021230077 @default.
- W2746456353 creator A5023116107 @default.
- W2746456353 creator A5026151069 @default.
- W2746456353 creator A5027328800 @default.
- W2746456353 creator A5029801761 @default.
- W2746456353 creator A5030931265 @default.
- W2746456353 creator A5031078301 @default.
- W2746456353 creator A5031323405 @default.
- W2746456353 creator A5031370568 @default.
- W2746456353 creator A5031690184 @default.
- W2746456353 creator A5032464400 @default.
- W2746456353 creator A5033256635 @default.
- W2746456353 creator A5041206856 @default.
- W2746456353 creator A5042432109 @default.
- W2746456353 creator A5043526996 @default.
- W2746456353 creator A5044134864 @default.
- W2746456353 creator A5048992211 @default.
- W2746456353 creator A5053291056 @default.
- W2746456353 creator A5056567340 @default.
- W2746456353 creator A5059996169 @default.
- W2746456353 creator A5060449393 @default.
- W2746456353 creator A5061620214 @default.
- W2746456353 creator A5063351800 @default.
- W2746456353 creator A5063473257 @default.
- W2746456353 creator A5070096873 @default.
- W2746456353 creator A5070132319 @default.
- W2746456353 creator A5077169512 @default.
- W2746456353 creator A5082092102 @default.
- W2746456353 creator A5086815330 @default.
- W2746456353 creator A5087573996 @default.
- W2746456353 creator A5091433944 @default.
- W2746456353 date "2017-09-01" @default.
- W2746456353 modified "2023-10-06" @default.
- W2746456353 title "Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial" @default.
- W2746456353 cites W1966724636 @default.
- W2746456353 cites W1978377409 @default.
- W2746456353 cites W1984065010 @default.
- W2746456353 cites W2022297754 @default.
- W2746456353 cites W2026448323 @default.
- W2746456353 cites W2044436186 @default.
- W2746456353 cites W2073140442 @default.
- W2746456353 cites W2090215736 @default.
- W2746456353 cites W2090946356 @default.
- W2746456353 cites W2114217833 @default.
- W2746456353 cites W2114455817 @default.
- W2746456353 cites W2119967034 @default.
- W2746456353 cites W2125721471 @default.
- W2746456353 cites W2126816979 @default.
- W2746456353 cites W2128084036 @default.
- W2746456353 cites W2139260559 @default.
- W2746456353 cites W2141105112 @default.
- W2746456353 cites W2143425592 @default.
- W2746456353 cites W2148758597 @default.
- W2746456353 cites W2149858388 @default.
- W2746456353 cites W2167021542 @default.
- W2746456353 cites W2212499331 @default.
- W2746456353 cites W2319551854 @default.
- W2746456353 cites W2486629951 @default.
- W2746456353 cites W2541820485 @default.
- W2746456353 cites W2559750299 @default.
- W2746456353 cites W2593617117 @default.
- W2746456353 cites W2604776612 @default.
- W2746456353 cites W2737964630 @default.
- W2746456353 cites W2892218501 @default.
- W2746456353 cites W4293241248 @default.
- W2746456353 doi "https://doi.org/10.1016/s2352-3026(17)30140-0" @default.
- W2746456353 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5718627" @default.
- W2746456353 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28826616" @default.
- W2746456353 hasPublicationYear "2017" @default.
- W2746456353 type Work @default.
- W2746456353 sameAs 2746456353 @default.
- W2746456353 citedByCount "128" @default.
- W2746456353 countsByYear W27464563532017 @default.
- W2746456353 countsByYear W27464563532018 @default.
- W2746456353 countsByYear W27464563532019 @default.
- W2746456353 countsByYear W27464563532020 @default.
- W2746456353 countsByYear W27464563532021 @default.
- W2746456353 countsByYear W27464563532022 @default.
- W2746456353 countsByYear W27464563532023 @default.
- W2746456353 crossrefType "journal-article" @default.
- W2746456353 hasAuthorship W2746456353A5003055083 @default.
- W2746456353 hasAuthorship W2746456353A5005645874 @default.
- W2746456353 hasAuthorship W2746456353A5005732386 @default.
- W2746456353 hasAuthorship W2746456353A5007847102 @default.
- W2746456353 hasAuthorship W2746456353A5011276712 @default.
- W2746456353 hasAuthorship W2746456353A5012400900 @default.
- W2746456353 hasAuthorship W2746456353A5015342719 @default.
- W2746456353 hasAuthorship W2746456353A5021230077 @default.
- W2746456353 hasAuthorship W2746456353A5023116107 @default.